Clinical Trial

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal biological dose (OBD).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-04-25; most recent amendment 2026-03-18.
Status change: Not Yet Recruiting → Recruiting 2024-06-21
Trial Details
NCT Number NCT06389877
Lead Sponsor Beam Therapeutics Inc.
Conditions Alpha 1-Antitrypsin Deficiency
Enrollment 106 participants
Start Date 2024-06-19
Primary Completion 2028-05 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2026-03-20